Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To evaluate and compare the OS of subjects with advanced or metastatic HER2 negative breast cancer when treated with ruxolitinib in combination with capecitabine versus capecitabine alone.
Inclusion criteria
- Metastatic or advanced HER-2 negative breast cancer patients who have already received treatment with anthracyclines and paclitaxel